Nectar Lifesciences Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: NECLIFE BSE: 532649

₹10.50

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #117 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Nectar Lifesciences Limited (this stock)	204	22.3	-50.3%	-25.6%	—	22	84	12

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹204 Cr

EV / EBITDA

14.3x

EV / Sales

40.70x

Market cap / Sales

40.70x

Earnings yield

4.48%

Quarterly Financials

Download CSV

Standalone Consolidated

↓ Negative

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 6 Cr, down 97.8% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	0	-22	-13	₹-0.6900
March 31, 2026	0	-57	-68	₹-1.8500
Dec. 31, 2025	0	57	14	₹3.0200
Sept. 30, 2025	5	-1	-176	₹-0.0100
June 30, 2025	281	-97	-63	₹-2.8200
March 31, 2025	431	-188	-130	₹-5.8000
Dec. 31, 2024	455	13	8	₹0.3500
Sept. 30, 2024	428	9	6	₹0.2500
June 30, 2024	359	5	3	₹0.1300
March 31, 2024	441	11	1	₹0.0300
Dec. 31, 2023	452	2	2	₹0.0700
Sept. 30, 2023	398	2	1	₹0.0500
June 30, 2023	394	3	2	₹0.0800

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	6	8	1	6	281	431	456	429	360	443	453	409	395
Operating revenue	0	0	0	5	281	431	455	428	359	441	452	398	394
Other income	6	8	1	1	0	0	1	1	1	1	0	11	0
Operating expenses	28	59	2	6	343	585	410	385	319	393	410	371	359
Operating profit	-28	-59	-2	-1	-62	-154	45	43	40	49	42	27	36
Operating profit margin	-184450.0%	—	—	-20.9%	-22.1%	-35.8%	9.8%	10.1%	11.1%	11.0%	9.3%	6.8%	9.0%
Depreciation	0	0	0	0	17	16	16	16	15	15	15	15	15
Interest	0	6	30	0	19	18	17	20	20	24	25	21	18
Exceptional items, gain / (loss)	—	—	88	—	—	—	—	—	—	—	—	—	—
Profit before tax	-22	-57	57	-1	-97	-188	13	9	5	11	2	2	3
Tax	-8	-20	-11	-0	-34	-58	5	3	2	11	1	1	1
Net profit	—	—	—	—	—	—	8	6	3	1	2	1	2
EPS	-0.69	-1.85	3.02	-0.01	-2.82	-5.80	0.35	0.25	0.13	0.03	0.07	0.05	0.08
Net profit (TTM)	—	—	—	—	—	—	17	11	6	5	10	-1	-25
EPS (TTM)	0.47	-1.66	-5.61	-8.28	-8.02	-5.07	0.76	0.48	0.28	0.23	0.44	-0.04	-1.09

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	0	-88	-293
March 31, 2025	1,673	-162	-114
March 31, 2024	1,686	18	5
March 31, 2023	1,525	-41	-22

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	-81.9%	-64.0%	9^†	1,675^†	1,699^†	1,567^†	1,680^†	1,546^†	2,367^†	2,791^†	1,953^†	1,691^†
Operating revenue	—	—	0	1,673	1,686	1,525	1,668^†	1,543^†	2,363^†	2,785^†	1,947^†	1,669^†
Other income	—	—	9^†	2^†	13^†	42^†	11^†	3^†	4^†	6^†	6^†	22^†
Operating expenses	—	—	409^†	1,700^†	1,533^†	1,469^†	1,509^†	1,433^†	2,145^†	2,521^†	1,711^†	1,352^†
Operating profit	—	—	-409^†	-26^†	153^†	56^†	159^†	110^†	218^†	264^†	236^†	316^†
Operating profit margin	—	—	—	-1.6%^†	9.1%^†	3.7%^†	9.5%^†	7.1%^†	9.2%^†	9.5%^†	12.1%^†	19.0%^†
Depreciation	—	—	17^†	62^†	61^†	59^†	57^†	60^†	61^†	63^†	64^†	62^†
Interest	—	—	55^†	75^†	87^†	79^†	79^†	112^†	126^†	148^†	115^†	117^†
Exceptional items, gain / (loss)	—	—	88^†	0^†	0^†	0^†	0^†	-25^†	0^†	0^†	0^†	0^†
Profit before tax	—	—	-88	-162	18	-41	34^†	-85^†	36^†	59^†	63^†	67^†
Tax	—	—	-64^†	-48^†	13^†	-18^†	9^†	-12^†	6^†	11^†	10^†	12^†
Net profit	—	—	-293	-114	5	-22	25^†	-73^†	30^†	47^†	52^†	55^†
EPS	—	—	-1.66^†	-5.07^†	0.23^†	-0.99^†	1.12^†	—	1.34^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	—	-1.6%^†	9.1%^†	3.7%^†	9.5%^†	7.1%^†	9.2%^†	9.5%^†	12.1%^†	19.0%^†
EBIT margin	—	-5.2%^†	6.3%^†	2.5%^†	6.8%^†	1.8%^†	6.8%^†	7.4%^†	9.1%^†	11.1%^†
PBT margin	—	-9.7%	1.1%	-2.7%	2.1%^†	-5.5%^†	1.5%^†	2.1%^†	3.2%^†	4.0%^†
Net margin	—	-6.8%	0.3%	-1.5%	1.5%^†	-4.7%^†	1.3%^†	1.7%^†	2.7%^†	3.3%^†
Interest coverage	-0.60x^†	-1.17x^†	1.21x^†	0.49x^†	1.44x^†	0.24x^†	1.28x^†	1.40x^†	1.54x^†	1.57x^†
Dividend payout	—	—	0.0%^†	—	0.0%^†	—	3.7%^†	—	—	—
Earnings retention	—	—	100.0%^†	—	100.0%^†	—	96.3%^†	—	—	—
Current ratio	9.61x	1.21x	—	—	—	—	—	—	—	—
Quick ratio	9.60x	0.54x	—	—	—	—	—	—	—	—
Debt to equity	0.00x	0.61x	—	—	—	—	—	—	—	—
Return on equity	-50.3%	-11.9%	—	—	—	—	—	—	—	—
Return on assets	-47.8%	-5.6%	—	—	—	—	—	—	—	—
Return on capital employed	-5.6%^†	-8.5%^†	—	—	—	—	—	—	—	—
Asset turnover	0.00x	0.82x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	-417	1,205	-699	12	-429
March 31, 2025	169	-42	-128	44	126
March 31, 2024	225	-17	-205	29	195
March 31, 2023	133	52	-186	30	103
March 31, 2022	95	17	-119	25	70

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	612	582	563	0	0	250	26	0	3	0
March 31, 2025	2,047	956	934	522	60	1,238	1,022	19	577	690
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.